Business Context and Reporting Period
This Form 8-K reports on events occurring on July 18, 2025, and July 24, 2025, for Pyrophyte Acquisition Corp. II, a Cayman Islands-based special purpose acquisition company (SPAC). The filing details the consummation of the Company's Initial Public Offering (IPO), a concurrent private placement, and the partial exercise of an over-allotment option.
Key Financial Metrics
- IPO Gross Proceeds: $175,000,000 from the sale of 17,500,000 Units at $10.00 per Unit.
- Private Placement Proceeds: $5,050,000 from the sale of 5,050,000 warrants to the Sponsor at $1.00 per warrant.
- Over-Allotment Proceeds: $25,411,500 from the sale of 2,541,150 additional Units at $10.00 per Unit.
- Total Trust Account Balance: $200,411,500 deposited in a U.S.-based trust account.
- Deferred Underwriting Commission: $7,875,000 included in the initial trust deposit.
- Warrant Exercise Price: $11.50 per share.
Material Changes
The Company transitioned from a pre-IPO entity to a publicly traded company on the New York Stock Exchange (NYSE) under the symbols PAII.U (Units), PAII (Class A Ordinary Shares), and PAII WS (Warrants). The capital structure was established through the IPO and private placement. Following the partial exercise of the over-allotment option on July 24, 2025, the Sponsor forfeited 30,231 Class B ordinary shares, leaving the Sponsor with an aggregate of 7,135,721 founder shares.
Outlook and Management Commentary
The filing confirms the successful closing of the IPO and the deposit of proceeds into the Trust Account, which is maintained by Continental Stock Transfer & Trust Company. An audited balance sheet as of July 18, 2025, reflecting these proceeds, is included as Exhibit 99.1. The Company is designated as an emerging growth company. No specific forward-looking guidance regarding a target acquisition or timeline is provided in this specific filing text.
Investor Verification Checklist
- Verify the final number of outstanding Class A ordinary shares and warrants post-over-allotment.
- Confirm the exact terms of the deferred underwriting commission ($7,875,000) and its impact on net proceeds available for operations.
- Review the audited balance sheet (Exhibit 99.1) for the precise cash position and working capital requirements.
- Monitor the status of the remaining over-allotment option (up to 83,850 Units) if not fully exercised.
- Check for any subsequent filings regarding the identification of a target business for the SPAC merger.